Respiratory System Diseases
Respiratory system diseases encompass a wide range of conditions that affect the lungs and airways, leading to significant morbidity and mortality worldwide. Our company is at the forefront of drug and therapy development services. Our expertise lies in understanding the underlying mechanisms, identifying potential therapeutic targets, and developing innovative therapies.
Introduction to Respiratory System Diseases
Respiratory system diseases, also called lung diseases, refer to a group of disorders that affect the lungs and airways, impairing their normal function. Respiratory system diseases can cause a range of symptoms, including coughing, wheezing, shortness of breath, and chest discomfort. These diseases, including but are not limited to asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF). The respiratory system plays a vital role in oxygen exchange and removing waste gases from the body.
Pathogenesis of Respiratory System Diseases
Respiratory system diseases can have various causes, including genetic factors, infections, environmental exposures, and lifestyle choices such as smoking. For instance, asthma, a chronic inflammatory disease of the airways, often has a genetic predisposition combined with environmental triggers like allergens or irritants. On the other hand, COPD is primarily caused by long-term exposure to harmful substances, particularly cigarette smoke.
Fig.1 Tissue structure of the respiratory system. (Kiyokawa, Hirofumi, et al., 2020)Targeted Therapies for Respiratory System Diseases
Inflammation and Immune Modulation
Inflammatory processes play a significant role in many respiratory system diseases. Targeting specific inflammatory pathways and modulating immune responses can help alleviate symptoms and slow disease progression.
Airway Remodeling and Fibrosis
Chronic respiratory diseases often involve structural changes in the airways and lung tissue. Developing therapies that target and prevent excessive airway remodeling and fibrosis can help preserve lung function and improve respiratory system diseases.
Bronchodilation and Airway Clearance
Enhancing bronchodilation and promoting effective airway clearance are crucial aspects of therapy development for diseases like asthma and COPD. Targeting specific receptors and pathways involved in bronchodilation can improve airway function and relieve symptoms.
Genetic and Molecular Defects
Genetic mutations and molecular defects underlie conditions such as cystic fibrosis. By developing therapies that target these specific defects, we aim to correct or compensate for the underlying genetic abnormalities.
Approved Therapies for Respiratory System Diseases
| Indication | Generic name | Target | Biomarker | Date of approval |
|---|---|---|---|---|
| NSCLC | Atezolizumab | PDL1 | PDL1 expression | 2016 |
| Necitumumab | EGFR | EGFR expression | 2016 | |
| Nivolumab | BMS | PDL1 expression | 2015-2016 | |
| Pembrolizumab | PD1 | PDL1 expression | 2015 | |
| Ramucirumab | VEGFR | VEGF/VEGFR expression | 2015 | |
| Asthma | Benralizumab | IL5R | EOS count | 2017 |
| Reslizumab | IL5 | EOS count | 2016 | |
| Omalizumab | IgE | IgE in serum | 2015-2016 | |
| Mepolizumab | IL5 | EOS count | 2015 | |
| RSV | Palivizumab | F-protein | Viral load/Neurotrophins in airways | 1998 |
| B.anthracis | Obiltoxaximab | PA-antigen | PA in serum | 2016 |
| Raxibacumab | PA-antigen | PA in serum | 2013 |
Our Services
At our company, we are dedicated to advancing diagnostics and therapy development for respiratory system diseases. We offer a comprehensive range of services, including target identification and validation, drug discovery and development, drug safety evaluation, and pharmacokinetic analysis.
Rare Types of Respiratory System Diseases
- Cystic Fibrosis (CF)
- Idiopathic pulmonary fibrosis (IPF)
- Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
- Acute Respiratory Distress (ARD)
- Acute Interstitial Pneumonia (AIP)
- Asthma
- Recurrent Respiratory Papillomatosis (RRP)
- Pneumocystosis
- Plastic Bronchitis (PB)
- Sarcoidosis (SS2)
- Kartagener Syndrome
Therapy Development Platforms
Our company specializes in developing and utilizing relevant animal models that mimic respiratory system diseases, allowing us to assess the therapeutic potential of our drug candidates. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Kiyokawa, Hirofumi, and Mitsuru Morimoto. "Notch signaling in the mammalian respiratory system, specifically the trachea and lungs, in development, homeostasis, regeneration, and disease." Development, Growth & Differentiation 62.1 (2020): 67-79.
- Sécher, Thomas, et al. "Therapeutic antibodies: A new era in the treatment of respiratory diseases?." Pharmacology & therapeutics 189 (2018): 149-172.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
